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Abstract
Background: Non-invasive measurement of tumor hypoxia has demonstrated potential for the evaluation of
disease progression, as well as prediction and assessment of treatment outcome. [18F]fluoroazomycin arabinoside
(FAZA) positron emission tomography (PET) has been identified as a robust method for quantification of hypoxia
both preclinically and clinically. The goal of this investigation was to evaluate the feasibility and value of repeated
FAZA-PET imaging to quantify hypoxia in tumors that received multi-dose chemotherapy.
Methods: FAZA-PET imaging was conducted over a 21-day period in a mouse xenograft model of HT-29 human
colorectal carcinoma, following multi-dose chemotherapy treatment with irinotecan (CPT-11) or nanoliposomal
irinotecan (nal-IRI, MM-398).
Results: Tumors treated with 10 mg/kg nal-IRI maintained significantly lower levels of hypoxia and smaller
hypoxic fractions compared to tumors that received 50 mg/kg CPT-11. Specifically, differences in FAZA uptake
were detectable 9 days before any significant differences in tumor volume were observed between the
treatment groups.
Conclusions: These findings highlight the potential use of FAZA-PET as an early marker of treatment response
following multi-dose chemotherapy.
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Background
Tumor hypoxia is strongly linked to aggressive disease
progression and resistance to therapy [1]. Specifically,
hypoxia-induced chemoresistance is associated with (1)
reduced intratumoral perfusion, which hinders drug
access to hypoxic areas; and (2) the quiescent state of
hypoxic cells, which render DNA structure modifying
chemo agents ineffective. The degree of hypoxia is a dy-
namic quantity that is influenced by physiological
factors. It is therefore important to assess hypoxia in
tumors before, during, and after therapy.
Advances in non-invasive imaging have resulted in the
development and clinical exploration of a number of
hypoxia targeted agents for positron emission tomog-
raphy (PET), including [18F]fluoromisondazole (FMISO)
[2, 3], [18F]fluoroazomycin arabinoside (FAZA) [4–11],
[64Cu]diacetyl-bis(N4-methylthiosemicarbazone (ATSM)
[12–14], and [18F]flortanidazole (HX4) [15–19]. Recent
reports have shown that [18F]FAZA may offer superior
sensitivity in the detection of hypoxic regions due to faster
systemic clearance from non-hypoxic tissues and, there-
fore, lower non-specific background activity compared to
[18F]FMISO [20]. In addition, preclinical validation has
demonstrated a good agreement between intratumoral
FAZA uptake, Eppendorf electrode measurements, and
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pimonidazole staining [5], while [64Cu]ATSM failed to
show good correlation with carbonic anhydrase IX (CAIX)
immunostaining [21]. Furthermore, FAZA-based PET
quantification of hypoxia proved to be highly reprodu-
cible in untreated animals when imaged 24 h apart [6].
Both preclinical and clinical reports have shown en-
couraging prognostic and predictive power of FAZA-
PET-based hypoxia imaging, particularly when used in
conjunction with radiotherapy [4, 8, 9]. These findings
support the employment of FAZA-PET as an effective
imaging technique to quantify hypoxia. Although other
PET-based tracers such as [18F]-fluorodeoxygluocose
(FDG) and [18F]-fluorothymidine (FLT) have shown po-
tential in predicting early treatment response in pa-
tients and animal models of cancer [22, 23], they do
not directly provide information on the hypoxia status
of a tumor.
Nanoliposomal irinotecan (nal-IRI, MM-398) is a
highly stable liposomal nanocarrier formulation of iri-
notecan hydrochloride (CPT-11) that significantly pro-
longs the pharmacokinetics and tumor bio-distribution
of the free drug [24, 25]. Nal-IRI greatly increases the
duration of the therapeutically active metabolite, SN-
38, within tumors, which becomes a better correlate to
in vivo activity of either free or nanoliposomal irinote-
can than SN-38 exposure when measured as the area-
under-the-curve (AUC) [24]. Nal-IRI has shown activity
in a number of preclinical tumor models [24, 25] and
has met its clinical endpoint in a phase III clinical trial in
gemcitabine-refractory pancreatic cancer [26], a tumor in-
dication that is characterized by low vascular density as
well as numerous and severe hypoxic regions [27].
We and others have observed that sustained exposure
as provided by nanoformulations of irinotecan can reduce
levels of hypoxia or hypoxia-regulated protein markers
relative to untreated tumors after either prolonged treat-
ment [28] or as immediate as following a single-dose
administration. However, such endpoint assessments do
not provide a comprehensive description of the dynamic
changes in tumor hypoxia characteristics during exposure
to a course of irinotecan-based chemotherapy, and no
investigation to date has explored the feasibility and per-
formance of hypoxia imaging for quantification of acute
(i.e., hours) and chronic (i.e., days) hypoxia changes in
such a setting. Here, we report the use of FAZA-PET for
repeated and longitudinal monitoring of tumor hypoxia
changes in a mouse xenograft model of HT-29 colorectal
cancer before, during, and after three weekly chemother-
apy administrations of either free irinotecan or nal-IRI.
Methods
Animal model
Studies were approved by the University Health Network
Animal Care Committee and adhered to the ethical
guidelines of the Canadian Council on Animal Care.
Female, 6- to 8-week-old NOD/SCID mice (Ontario
Cancer Institute, Toronto, Canada) were inoculated sub-
cutaneously with 1 × 107 HT-29 human colorectal
adenocarcinoma cells (ATCC, Manassas, VA, USA), in a
100 μL injection volume, at both dorsal flank sites such
that each mouse bore bilateral tumors. HT-29 cells repre-
sent a goblet-like subtype of colorectal adenocarcinoma
[29]. Tumor growth was monitored using caliper-based
measurements. Studies began 17 days post-inoculation,
when tumors reached a mean volume of 307.5 ±
131.7 mm3 (15 mice, 30 tumors).
Chemotherapy treatment
Animals (n = 15) were randomized into three treatment
groups: (1) irinotecan hydrochloride (referred to as iri-
notecan hereafter) administered at 50 mg/kg, (2) nal-
IRI at 5 mg/kg, and (3) nal-IRI at 10 mg/kg. Based on a
mechanistic pharmacokinetic model, 10 mg/kg of nal-
IRI or 50 mg/kg irinotecan was estimated to result in
similar AUC exposure to SN-38 in both plasma and
tumor, while 5 mg/kg nal-IRI and 50 mg/kg irinotecan
showed a comparable duration of SN-38 levels above a
critical intratumoral threshold of 120 nmol/L [24]. All
treatment doses were known to suboptimally control
tumor growth in the bilateral subcutaneous HT-29
tumor model. Each treatment group was composed of a
total of 10 tumors (five animals bearing two tumors
each). A total of four weekly administrations were given
i.v. on day 0, 7, 15, and 21.
In vivo imaging
A total of seven FAZA-PET/CT imaging sessions were
performed on day 0, 2, 4, 7, 10, 16, and 21 following
initiation of treatment using a triple mouse imaging
bed (Fig. 1). [18F]FAZA was produced by CanProbe
(Ontario, Canada) with a radiochemical purity of 95.7
± 3.7 % (calculated over seven productions). PET im-
aging (Focus 220, Siemens) was performed at 2-h
post-FAZA administration (0.79 ± 0.06 MBq/g of body
weight, Additional file 1: Figure S1). Imaging at 2-h
post-FAZA injection was reported to be a desirable im-
aging time point based on tracer kinetics at the tumor site
(i.e., reaching steady state) and on the fact that at this
time, post-injection, the tumor tracer uptake levels corre-
lated well with tissue hypoxia [5, 30]. Each PET acquisi-
tion consisted of a 20-min emission scan followed by
an 8-min 57Co transmission scan for attenuation and
scatter correction. Then, a CT scan (GE Locus Ultra,
80 kVp, 50 mA) was performed with animals in the
same position in order to provide anatomical data for
image registration. Treatment response was quantified
based on CT tumor volumes.
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Image analysis
The PET and CT datasets were registered, contoured,
and analyzed using the Inveon Research Workplace soft-
ware (IRW 4.0, Siemens). The hypoxic fraction is defined
as the number of tumor voxels with FAZA-PET signal
values above a set threshold over the total number of
tumor voxels. The hypoxia signal threshold value was
defined as the mean FAZA-PET signal value measured
in the upper leg muscle of the same mouse + 3 standard
deviations [31].
Histology
Tumor-specific hypoxia status at the study endpoint
(day 22) was confirmed by immunohistochemistry.
Animals received an intraperitoneal administration of
EF5 (0.1 mM EF5/g body weight) 2 h before euthan-
asia, and portions of the excised tumors were fixed,
sectioned, and stained for hematoxylin and eosin
(H&E), EF5 (anti-EF5 ELK3-51), and CAIX (anti-CAIX
M75). Image acquisition was done with an Aperio
Scanscope AT. Analysis of the histology images were
performed using Definiens Tissue Studio (Definiens
AG, Munich, Germany).
Statistical analysis
Differences between means for the different treatment
groups were compared using one-way ANOVA or an
independent samples t test where equal variances are
not assumed and with a confidence interval of 95 %. Dif-
ferences between means for the same treatment group
on different days were compared using a paired-samples
t test with a confidence interval of 95 %. All statistical
calculations were performed using SPSS version 22
(IBM, Armonk, NY, USA).
Results and discussion
Treatment group randomization and baseline FAZA
uptake
In order to ensure that the response is consistent across
animals and tumors that received the same treatment,
mice bearing bilateral tumors were randomized into
three treatment groups (irinotecan at 50 mg/kg, nal-IRI
at 5 mg/kg, and nal-IRI at 10 mg/kg) based on pre-
treatment growth kinetics (Fig. 2a) and caliper-measured
tumor volume at treatment day 0 (Fig. 2b). Figure 2a
shows no significant difference in the tumor growth curves
from day 7 to day 17 post-tumor inoculation. Figure 2b
illustrates the mean CT tumor volumes for each group (a
total of 10 tumors in 5 mice per group), assessed after ani-
mals were already randomized on the day of treatment
initiation. No statistically significant difference was found
among groups (p = 0.202 for CT-measured tumor vol-
umes, p = 0.539 for caliper-measured tumor volumes).
The correlation (R2 = 0.904, Additional file 1: Figure S2)
a
b
Fig. 1 Illustration of a the triple mouse PET imaging set-up and b the experimental workflow. Day 0 corresponds to the day of treatment
initiation. Note that the fur of the mice was colored for identification purposes
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between the tumor volumes estimated based on digital
caliper measurements and CT volume contours was
within a 10 % tolerance (caliper volume = 0.938 × CT
volume, 30 tumors over 7 measurement days).
On the day of treatment initiation, baseline FAZA up-
take in mean %ID/g for both tumor and muscle (ROI
drawn on the inner thigh muscle) was calculated. No
statistically significant differences between the baseline
tumor uptake for the three groups was found (p = 0.579,
tumor uptake = 1.40 ± 0.41 to 1.62 ± 0.50 %ID/g, Fig. 2c).
Most importantly, no correlation (R2 = 0.008, Fig. 2d)
was found between the mean FAZA tumor uptake and
the CT tumor volume at study baseline (on the day of
treatment initiation). Muscle FAZA uptake (Additional
file 1: Figure S3) averaged ~50 % of the uptake measured
in tumors at baseline consistent with previous publica-
tions [4, 8]. The differences measured in the baseline
mean FAZA muscle uptake among the three treatment
groups were relatively small (0.58 ± 0.18 %ID/g for the
irinotecan group, 0.78 ± 0.32 %ID/g for the 5 mg/kg nal-
IRI group, and 0.80 ± 0.18 %ID/g for the 10 mg/kg nal-
IRI group) and were not statistically significant (p =
0.304). Muscle FAZA uptake was not used to normalize
FAZA tumor uptake (i.e., to calculate tumor-to-muscle
ratios) at the various imaging time points, since a repro-
ducibility study previously conducted by our group [32]
a b
c d
Fig. 2 Study baseline data including a pre-treatment mean tumor growth kinetics for each group (day 17 post-inoculation corresponds to day 0
of treatment initiation), b the baseline tumor volume obtained by contouring the volumetric CT data sets (p = 0.202), c the pre-treatment tumor
(p = 0.579) and muscle (p = 0.304) FAZA uptake, and d the lack of correlation between tumor FAZA uptake and tumor volume. Each treatment
group is composed of 5 mice, each bearing bilateral subcutaneously implanted HT-29 colon cancer xenograft, for a total of 10 tumors per
treatment group
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had shown that there is higher day-to-day variation in
the muscle FAZA uptake compared to tumor.
Treatment time course FAZA uptake
Response to treatment was evaluated over a 3-week period
through CT-based tumor volume measurement (Fig. 3a).
The seven imaging sessions and the three treatment doses
were well-tolerated by all animals (Fig. 3b). The mean
FAZA uptake measured in the 30 tumors (15 mice) ranged
between 0.83 and 4.29 %ID/g over the course of the study
(Fig. 3c). Treatment with 10 mg/kg nal-IRI maintained





Fig. 3 a Tumor volume changes and b animal weight fluctuations over the study period of 21 days. c Longitudinal tumor FAZA uptake (%ID/g)
and d tumor hypoxic fraction calculated from the PET data set. Each data point (except for day 21, transparently masked in gray) represents the
mean ± standard deviation obtained from five animals, each bearing bilateral tumors, for a total of 10 tumors per treatment group. Asterisk denotes
statistically significant difference (p < 0.05) between the nal-IRI (10 mg/kg) and either one or both the other two treatment groups. e Three sets of rep-
resentative PET image (left) and CAIX (middle) and EF5 (right) stained tumor sections obtained from three animals, one belonging to each treatment
group. Qualitative demonstration that the degree of FAZA-PET signal is confirmed by the level of CAIX and EF5 immunohistochemistry staining (i.e.,
high FAZA uptake correlates to high CAIX and high EF5 staining)
Zheng et al. EJNMMI Research  (2015) 5:57 Page 5 of 10
fractions compared to tumors that received irinotecan
(Fig. 3c, d), and these differences between the treatment
groups were significant as early as day 7 post-treatment
initiation (Table 1). Tumor growth control was also appar-
ent in the 10 mg/kg nal-IRI treatment group (Fig. 3a).
However, differences in tumor volume only became statis-
tically significant on day 10 (nal-IRI at 10 mg/kg vs. irino-
tecan at 50 mg/kg, p = 0.038) and day 16 (nal-IRI at
10 mg/kg vs. irinotecan at 50 mg/kg, p = 0.006; nal-IRI at
10 mg/kg vs. nal-IRI at 5 mg/kg, p = 0.029) (Table 1). This
suggests that tumor hypoxia imaging using FAZA-PET
has the potential to provide early prediction of treatment
response. Five animals (one from each of the nal-IRI
groups and three from the irinotecan treatment group)
were sacrificed between day 16 and 21 for ethical reasons
(tumor ≥ 1.5 cm in any direction). As a result, the data re-
ported for day 21 only represents the surviving subgroup
and is therefore skewed toward better response as shown
by an overall decrease in tumor FAZA uptake (Fig. 3c). It
is interesting to note that the tumor hypoxic fraction
measure (Fig. 3d) better correlates with tumor response on
day 21 (Fig. 3a) than the mean FAZA tumor uptake
(Fig. 3c). This suggests that quantification of tumor hyp-
oxia using the hypoxic fraction measure may be a more re-
liable evaluation metrics than the mean FAZA uptake
value.
Initial histological validation of the FAZA-PET signal
was done by staining with two distinct hypoxia
markers, CAIX and EF5, on adjacent tumor tissue
slides (Fig. 3e). The degree of FAZA-PET tumor uptake
is proportional to the amount of CAIX and EF5 positive
staining. Specifically, the percent CAIX and EF5 posi-
tive tumor areas for the 10 mg/kg nal-IRI group (17.6
± 7.4 % and 1.9 ± 1.6 %, respectively) are significantly
lower (p < 0.05) compared to those treated with 5 mg/
kg of nal-IRI (28.8 ± 8.5 % and 5.8 ± 3.9 %, respectively)
and 50 mg/kg of irinotecan (29.2 ± 5.5 % and 9.2 ±
4.7 %, respectively) This is in agreement with the sig-
nificantly lower FAZA-positive tumor fraction quanti-
fied using the PET data (Table 1). A decrease in cellular
density following treatment with nal-IRI at 10 mg/kg
compared to the other treatments was also observed
(Fig. 4).
Longitudinal changes in tumor FAZA uptake
Relative changes in tumor volume and hypoxia over
time with respect to baseline values (day 0) were calcu-
lated for each tumor individually. The relative change
in FAZA uptake in tumors over the 16-day period com-
pared to baseline is shown in Fig. 5a. An increase in
median FAZA uptake can be observed for the group
that received 50 mg/kg of irinotecan starting as early as
4-day post-treatment initiation and for the group that
received 5 mg/kg of nal-IRI 7-day post-treatment initi-
ation. Only with the nal-IRI treatment at 10 mg/kg did
the tumors maintain their pre-treatment hypoxia level
on day 7 (p = 0.264 with respect to day 0 baseline
values, paired-samples t test) and beyond following
treatment initiation, despite significant increases in
their tumor volumes (p < 0.005 for day 7, volumes with
respect to day 0 baseline, paired-samples t test). Thus,
the treatment with 10 mg/kg nal-IRI was able to
stabilize the hypoxia levels in tumors. In addition, dis-
ease progression in terms of tumor volume increase
was better controlled in this treatment group compared
to the other two treatment groups (Fig. 3a).
Normalized time course trajectories for individual tu-
mors of changes in FAZA uptake and tumor volume
with respect to baseline values are shown in a three-
dimensional plot (Fig. 5b). Ellipsoidal contours were
generated for all trajectory data points from each treat-
ment group (ellipsoid coverage = 70 % of data points).
Table 1 P values calculated from independent samples t tests (two-tailed, equal variance not assumed) for tumor volume, tumor
FAZA uptake, and tumor hypoxic fraction parameters at various study time points.
Statistically significant difference in tumor FAZA uptake (expressed both in terms of %ID/g and tumor hypoxic fraction) is found on day 7 post-treatment initiation
between the nal-IRI (10 mg/kg) and the other two treatment groups. Statistically significant difference in tumor volume, for the same groups, is seen on day 10
and 16. A total of 10 tumors were included in the analysis for each group on days 4 through 16. On day 21, the number of tumors per group was 4, 6, and 8 for
irinotecan, nal-IRI (10 mg/kg) and nal-IRI (5 mg/kg), respectively
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We observed treatment-specific divergence among all
three treatment groups; data points from tumors treated
with 10 mg/kg nal-IRI were clustered around the smal-
lest changes in both tumor volume and FAZA uptake
(blue ellipsoid), while data points from tumors treated
with 50 mg/kg irinotecan were clustered around the lar-
gest changes (gray ellipsoid). The data points from tu-
mors treated with 5 mg/kg nal-IRI (red ellipsoid) were
shifted toward intermediate changes, particularly along
the percent change in FAZA uptake axis. In addition,
the trajectory path lengths of tumors treated with nal-
IRI at either 5 or 10 mg/kg were significantly different
(p = 0.0012, one-way ANOVA) from those treated with
free irinotecan (data not shown). This time course as-
sessment of individual tumor performance allowed for
identification of more subtle differences that was not ap-
preciated using group statistics alone.
Discussion
Longitudinal imaging studies are challenging to per-
form, even in well-controlled preclinical animal models.
In hypoxia imaging, the baseline hypoxia status of the
tumor can be significantly different even for tumors
originating from the same cell line with similar volumes
Fig. 4 Representative H&E stained tumor sections (20× magnification, day 16) showing a decrease in cellular density following treatment with
nal-IRI at a dose of 10 mg/kg compared to treatment with nal-IRI at 5 mg/kg and treatment with irinotecan at 50 mg/kg
a b
Fig. 5 a Longitudinal relative changes in tumor FAZA uptake with respect to pre-treatment values (%ID/g on day 0). Median values are plotted
with the interquartile range indicated by bars. Green asterisk and red asterisk indicate statistically significant difference with respect to the 50 mg/kg
irinotecan group and the 5 mg/kg nal-IRI group (p < 0.05), respectively. b Three-dimensional scatterplot of individual tumors at each treatment day
with regard to % change in FAZA uptake from baseline (day 0) and % tumor volume change from day 0. For each treatment group, contour ellipsoids
(ellipsoid coverage of data points = 70 %) are presented. Tumors are treated with 10 mg/kg nal-IRI (blue ellipsoid), 5 mg/kg nal-IRI (red ellipsoid), and
50 mg/kg irinotecan (gray ellipsoid)
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and growth rates. Considerable effort was thus taken to
minimize randomization bias as this could become
more pronounced over the course of repeated measure-
ments performed in the same animals and tumors. Our
study showed the feasibility of performing FAZA-PET
imaging for monitoring response to treatment, even in
a relatively heterogeneous group of tumors with higher
variability in pre-treatment tumor volume and hypoxia
level, when appropriate randomization steps are employed.
Using these methods, this study further demonstrated that
FAZA-PET imaging-based tumor hypoxia assessment may
be utilized as an early predictor of chemotherapy treat-
ment response. Specifically, our findings illustrate that dif-
ferences in tumor hypoxia can be detected significantly
earlier (3 to 9 days) than tumor volume differences be-
tween treatment groups.
Our results show no immediate hypoxia reduction, both
in terms of %ID/g of FAZA tumor uptake and tumor hyp-
oxic fraction, on days 2 to 4 after treatment with free iri-
notecan or nal-IRI. This is consistent with the mechanism
of action of camptothecins, which requires a prolonged
exposure time to SN-38 for maximum cytotoxic effects
[33]. Free irinotecan is rapidly cleared from plasma and
tumor tissue, thereby not allowing sufficient time for
tumor cells to be exposed to SN-38. Only with the nal-IRI
treatment at 10 mg/kg did the tumors maintain their pre-
treatment hypoxia level on day 7 and beyond following
treatment initiation, despite significant initial increases in
their tumor volumes, thus suggesting changes in the
tumor microenvironment. Previous experiments in an
HT-29 tumor model grown in NOD-SCID mice have
shown that the 10 mg/kg nal-IRI dose achieves a pro-
longed SN-38 tumor duration of ~96 h, while the ex-
posure with 50 mg/kg free irinotecan is ~36 h [24].
Similar to the published report on another liposomal
irinotecan formulation, irinophore C [28], data from
this study showed that tumors presented a less hypoxic
profile following the 10 mg/kg nal-IRI treatment, and
the prolonged SN-38 exposure resulted in decreased
cellular density thus potentially alleviating solid stress
and reducing blood vessel compression during tumor
growth [34]. It has been shown that irinotecan and
other camptothecins can inhibit the hypoxia-inducible
factor-1α (HIF-1α) protein accumulation in vivo. This
can interfere with the capacity of tumor cells to adapt
to a hypoxic environment [10] and may increase their
treatment sensitivity [1]. Furthermore, the modulation of
HIF-1α protein levels has been reported to occur inde-
pendently of significant changes in intratumoral hypoxia
[10]. However, this study was aimed at quantifying longi-
tudinal tumor hypoxia changes and could not address
these mechanistic questions.
Results from our investigation confirmed that a dose of
10 mg/kg of nal-IRI was sufficient to provide growth
control in the bilateral HT-29 subcutaneous xenograft
model, and it demonstrated a significant benefit in thera-
peutic response compared to the other two treatment
groups. The administration of a therapeutically more ef-
fective dose of nal-IRI (i.e., 20 mg/kg), while safe and effi-
cacious [35], would have reduced sensitivity in the
measurement of FAZA uptake due to potential disappear-
ance of tumor hypoxia following partial or complete re-
sponse and could also have introduced measurement bias
due to rapid tumor volume shrinkage. Dosing in murine
models for both nal-IRI and free irinotecan employed in
this study scales appropriately to the clinical setting where
nal-IRI is given at a dose density of 40 mg/m2/week [36].
The apparent discordance between FAZA uptake
(Fig. 3c) and hypoxic fraction (Fig. 3d) on day 21 post-
treatment initiation for the nal-IRI treated groups is likely
due to a decrease in focal areas of intense hypoxia which
diminishes the mean tumor FAZA uptake value, while the
overall volume fraction of hypoxia is maintained in the
tumor compared to day 16. This observation motivates
further studies aimed at investigating the intratumoral
hypoxia heterogeneity. In fact, more sophisticated image
analysis and acquisition strategies exist to further increase
the sensitivity of FAZA-PET for hypoxia measurement.
For example, quantification of intratumoral heterogeneity
can be performed both in terms of subregional steady-
state FAZA uptake and variations in distribution, as well
as uptake and clearance kinetics through the identification
of intratumoral multi-voxel clusters. In addition, kinetic
modeling of dynamic FAZA uptake enables improved
inter-tumor normalization achieved through the measure-
ment of the perfusion characteristics of each tumor during
the early imaging frames.
Conclusions
This study demonstrated the feasibility of performing lon-
gitudinal and repeated tumor hypoxia assessment using
FAZA-PET imaging for early prediction of treatment re-
sponse. Statistically significant differences in hypoxia
within tumor-size matched groups in response to different
treatments were successfully detected. Specifically, the li-
posomal irinotecan formulation nal-IRI showed enhanced
ability to halt progression of tumor hypoxia compared to
free irinotecan. Overall, hypoxia changes following anti-
cancer therapy has the potential to provide an early as-
sessment of treatment activity.
Additional file
Additional file 1: Figures S1–S3. Figure S1. Mean FAZA administration
dose (MBq/g) calculated for animals belonging to each treatment group
over 7 imaging sessions. Figure S2. Tumor volume correlation between
measurements performed using caliper and CT. Figure S3. Longitudinal
muscle FAZA uptake (%ID/g) measured from the CT data set over a 21-day
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period following the first treatment dose administration (day 0). Each data
point (except for day 21, transparently masked in gray) represents the mean
± standard deviation obtained from 5 animals. (PDF 86 kb)
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